Children's Oncology Group's 2023 blueprint for research: Non-Hodgkin lymphoma


Nader Kim El-Mallawany, Baylor College of Medicine, Department of Pediatrics, Texas Children's Hospital, Texas Children's Cancer Center, Houston, Texas, USA.
Sarah Alexander, Department of Paediatrics, Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada.
Mark Fluchel, Department of Pediatrics, Division of Pediatric Hematology/Oncology, Seattle Children's Hospital and University of Washington School of Medicine, Seattle, Washington, USA.
Robert J. Hayashi, Division of Pediatric Hematology/Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis Children's Hospital, Siteman Cancer Center, St. Louis, Missouri, USA.
Eric J. Lowe, Children's Hospital of The Kings Daughters, Department of Pediatrics, Division of Pediatric Hematology-Oncology, Norfolk, Virginia, USA.
Lisa Giulino-Roth, Department of Pediatrics, Weill Cornell Medical College, New York, New York, USA.
Birte Wistinghausen, Center for Cancer and Blood Disorders and Center for Cancer and Immunology Research, Department of Pediatrics, Children's National Research Institute, Children's National Hospital, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.
Michelle Hermiston, Department of Pediatrics, University of California, San Francisco, California, USA.
Carl E. Allen, Baylor College of Medicine, Department of Pediatrics, Texas Children's Hospital, Texas Children's Cancer Center, Houston, Texas, USA.

Document Type

Journal Article

Publication Date



Pediatric blood & cancer




Langerhans cell histiocytosis; clinical trial; non-Hodgkin lymphoma; pediatric oncology


Pediatric non-Hodgkin lymphoma (NHL) includes over 30 histologies (many with subtypes), with approximately 800 cases per year in the United States. Improvements in survival in NHL over the past 5 decades align with the overall success of the cooperative trial model with dramatic improvements in outcomes. As an example, survival for advanced Burkitt lymphoma is now >95%. Major remaining challenges include survival for relapsed and refractory disease and long-term morbidity in NHL survivors. Langerhans cell histiocytosis (LCH) was added to the NHL Committee portfolio in recognition of LCH as a neoplastic disorder and the tremendous unmet need for improved outcomes. The goal of the Children' Oncology Group NHL Committee is to identify optimal cures for every child and young adult with NHL (and LCH). Further advances will require creative solutions, including engineering study groups to combine rare populations, biology-based eligibility, alternative endpoints, facilitating international collaborations, and coordinated correlative biology.